A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Spira, A. I.; Spigel, D. R.; Camidge, D. R.; De Langen, A.; Kim, T. M.; Goto, K.; Elamin, Y. Y.; Shum, E.; Reckamp, K. L.; Rotow, J. K.; Goldberg, S. B.; Gadgeel, S. M.; Leal, T.; Albayya, F.; Fitzpatrick, S.; Louie-Gao, M.; Parepally, J.; Zalutskaya, A.; Yu, H. A. |
| Abstract Title: | A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305126 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS9142 |
| Notes: | Meeting Abstract: TPS9142 -- Meeting also held virtually -- Source: Wos |
